---
title: "Lukang Pharmaceutical Unit Gets China Approval for Type 2 Diabetes Drug"
date: "2025-02-11 16:27:35"
summary: "China's medical products administrator approved Shandong Lukang Pharmaceutical subsidiary Shandong Lukang Pharmaceutical Group Saite's linagliptin tablets for type 2 diabetes. The drug is a dipeptidyl peptidase 4 inhibitor, helping stimulate insulin release in a glucose-dependent manner, according to a Tuesday filing with the Shanghai Stock Exchange. Shares closed 3% lower..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

China's medical products administrator approved Shandong Lukang Pharmaceutical subsidiary Shandong Lukang Pharmaceutical Group Saite's linagliptin tablets for type 2 diabetes.

The drug is a dipeptidyl peptidase 4 inhibitor, helping stimulate insulin release in a glucose-dependent manner, according to a Tuesday filing with the Shanghai Stock Exchange.

Shares closed 3% lower during Tuesday's afternoon trading.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250211:G2466198:0/)
